08:29 AM EDT, 07/11/2024 (MT Newswires) -- Skye Bioscience ( SKYE ) said Thursday that it has established a clinical and scientific advisory board to support the development of Nimacimab for the treatment of obesity.

The company said the advisory board is composed of academics and metabolic disease experts, particularly those who specialize in obesity.

Nimacimab is expected to begin a mid-stage trial in patients with obesity in Q3, the company said.